Why the study?
Does oral ibopamine improve hemodynamic function in patients with idiopathic congestive cardiomyopathy?
Does oral ibopamine improve hemodynamic function in patients with idiopathic congestive cardiomyopathy?
A single 150 mg oral dose of ibopamine significantly improves hemodynamic parameters in patients with idiopathic congestive cardiomyopathy without causing acute side effects.
Answers are grounded in this paper and cite their sources.
May support acute hemodynamic effects of oral ibopamine in idiopathic cardiomyopathy; hypothesis-generating case report requiring controlled trials.
We administered 150 mg of ibopamine orally to 10 patients suffering from idiopathic congestive cardiomyopathy. Hemodynamic function was evaluated by right heart catheterization and by measurement of cardiac output with the thermodilution technique. Ibopamine caused no significant change in heart rate or mean arterial pressure. Cardiac index, stroke volume index, and left ventricular work index all increased significantly by about 30%. Mean pulmonary arterial pressure decreased by about 30%, and systemic vascular resistance decreased by about 20%. The effects peaked at about 3 h and lasted 5-7 h. No side effects were noted. These findings with invasive techniques confirm those of others using noninvasive techniques, and suggest that ibopamine may be useful in the treatment of congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Dei et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: